Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- PM Kishida Orders 3 Ministers to Map Out Overall COVID-19 Response Plan
October 5, 2021
- Innovative Drug Makers Log Sluggish Generic Use Rates: MHLW Data
October 5, 2021
- New Health Minister Goto Vows to Protect Secure Healthcare System in FY2022 Reform
October 5, 2021
- Nipocalimab, 3 Other APIs Earn Orphan Status in Japan
October 5, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW Panels
October 4, 2021
- Manabu Yoshida Becomes Vice Health Minister, Top Bureaucrat at MHLW
October 4, 2021
- No Factor to Impede Reinstatement of HPV Vaccine Recommendation: Panels
October 4, 2021
- Govt Must Prepare for Booster Shot Rollout before Year-End: Kono
October 4, 2021
- Ex-PMDA Chief Kondo, Credited with Eliminating Japan’s Drug Lag, Dies at 79
September 30, 2021
- Pharma Officials Air Hopes and Concerns for New LDP Leader, Eyes on MHLW Revamp
September 30, 2021
- GSK’s COVID-19 Drug to Be Allocated through Govt for Now
September 30, 2021
- MHLW Panel to Discuss HPV Vaccine Recommendation on Oct. 1
September 29, 2021
- Veklury’s Normal Distribution in Japan to Start from Oct. 18
September 29, 2021
- Reorganization of MHLW Inevitable: PM Suga
September 29, 2021
- Japan Approves Padcev, Entresto’s Hypertension Use, Lilly’s RET Inhibitor and More
September 28, 2021
- MHLW to Further Push Single-Product, Single-Price Trades, Prohibit Dumping in Revised Distribution Guidelines
September 28, 2021
- Japan Approves GSK’s COVID-19 Antibody Drug, 2nd Treatment for Mild Cases
September 28, 2021
- Secure Domestic Supply of Oral COVID-19 Med: Komeito to Govt
September 27, 2021
- MHLW Eyes Booster Shots for Healthcare Workers from December
September 24, 2021
- One-Month Business Suspension Order Likely for Choseido over Generic Recalls
September 24, 2021
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…